BBT-176 gets approval for Phase 1 and 2 trials by FDA

Home > Business > Industry

print dictionary print

BBT-176 gets approval for Phase 1 and 2 trials by FDA

Bridge Biotherapeutics said Monday that it has received approval from the U.S. Food and Drug Administration to start Phase 1 and 2 clinical trials for BBT-176.

BBT-176, a third-generation therapy for non-small cell lung cancer, will be tested with a small number of patients in Korea through a dose escalation study. The treatment from Bridge Biotherapeutics is separate from AstraZeneca’s Tagrisso.

BBT-176 will tested again in the United States and Korea. The studies will be used to observe safety, tolerability and anti-tumor efficacy of BBT-176 among patient groups.

The candidate substance, which was first discovered by the Korea Research Institute of Chemical Technology, was licensed to Bridge Biotherapeutics in late 2018.

By Ko Jun-tae
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now